Lv4
698 积分 2024-08-22 加入
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial
3天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
7天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
11天前
已完结
FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities
1个月前
已完结
A Cross-Species Reactive TIGIT-Blocking Antibody Fc Dependently Confers Potent Antitumor Effects
1个月前
已完结
An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-β with enhanced antitumor efficacies
2个月前
已完结
A trispecific antibody engaging T cells with tumour and myeloid cells augments antitumour immunity
2个月前
已完结
Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical Evaluation
3个月前
已完结
Target identification and assessment in the era of AI
4个月前
已完结
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies
5个月前
已关闭
皖公网安备34019202002308
